Cessation of Trading on PLUS & AIM Admission

RNS Number : 0088D

Eden Research plc

10 May 2012

 



GB0001646941/GBP/PLUS-exn

10 May 2012

EDEN RESEARCH PLC

("Eden" or "Company")

Cessation of Trading on PLUS Markets and Admission to Trading on AIM

Eden Research plc, the agrochemical and encapsulation development company, announces that withdrawal from trading of the Ordinary Shares on PLUS will take place at 4.30pm today and that Admission will become effective and dealings in the Ordinary Shares on AIM will commence at 8.00am on 11 May 2012 under the trading symbol EDEN.

Advantages of moving to AIM

The Directors now believe that additional advantages can be achieved through a move to AIM; notably in the areas of share liquidity, visibility of the business within its industry and greater investor interest.

The Directors of Eden are responsible for the contents of this announcement.

Eden Research plc	www.edenresearch.com
Clive Newitt, Managing Director	Tel: [phone]
Alex Abrey, Chief Financial Officer
Zeus Capital Limited	Tel: [phone]
Ross Andrews, Andrew Jones, Brian Stockbridge
Walbrook PR Ltd	Tel: [phone]
Paul McManus (Media Relations)	Mob: [phone] or [e-mail]
Paul Cornelius (Investor Relations)	Mob: [phone] or [e-mail]

Capitalised terms in this announcement are as defined in the Company's Admission document, which is available on the Company's website: www.edenresearch.com

Notes:

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest (2010: £172,000; 2011: £91,000) whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

For more information about Eden, please visit www.edenresearch.com 

 

END

 

 

MSCUKOSRUKAVRAR